

SOP: Training and Coverage Requirements for Investigators Conducting Clinical Trials and Clinical Investigations

NUMBER	DATE	AUTHOR	APPROVED BY	PAGE
HRP-093	08/23/2017	C. Gates	C. Kiel	1 of 1

1 PURPOSE

- 1.1 This policy establishes the requirements for investigators who conduct [clinical trials](#) and [clinical investigations](#).

2 REVISIONS FROM PREVIOUS VERSION

- 2.1 None

3 POLICY

- 3.1 Principal Investigators must ensure that all research personnel have completed the following training prior to conducting any research activities:
 - 3.1.1 For research involving only minimal risk:
 - 3.1.1.1 [NIH Program Protecting Human Research Participants](#);
 - 3.1.1.2 [CITI online Basic Human Research Protections Training for Biomedical Researcher](#); or
 - 3.1.1.3 [CITI online Basic Human Research Protections Social Behavioral Researchers and staff](#).
 - 3.1.2 For social behavioral clinical trials:
 - 3.1.2.1 [GCP – Social and Behavioral Research Best Practices for Clinical Research](#).
 - 3.1.3 For clinical investigations subject to FDA jurisdiction:
 - 3.1.3.1 [GCP for Clinical Trials with Investigational Drugs and Biologics \(ICH Focus\)](#); or
 - 3.1.3.2 [GCP for Clinical Trials with Investigational Medical Devices](#).
- 3.2 For biomedical trials involving greater than minimal risk, Principal Investigators must ensure that a responsible person is available to provide medical care to research participants whenever the principal investigator is unavailable to provide said care. This responsible person must:
 - 3.2.1 Be included on the Research Personnel List on the Electronic Initial Review Application or on [FORM HRP 215 Research Personnel List Template](#) if there is no electronic application.
 - 3.2.2 Have sufficient medical training to oversee the medical care of participants; and
 - 3.2.3 Have sufficient training on the protocol requirements to avoid deviations from the protocol requirements unless the deviation is necessary to prevent imminent harm to participants.
- 3.3 When a Principal Investigator leaves his/her position at UC Davis, s/he must perform one of the following actions with respect to all clinical trials and clinical investigations for which s/he is the Principal Investigator:
 - 3.3.1 Close the study;
 - 3.3.2 Transfer the study to a qualified Principal Investigator at UC Davis as outlined in the UC Davis Investigator Manual; or
 - 3.3.3 Work with IRB Administration to develop an alternative plan for supervision of the research.

4 MATERIALS

- 4.1 None

5 REFERENCES

- 5.1 None